Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...

Vertex is moving to high-grade production at its Reward gold mine as stoping gets underway at the 1670 airleg stope Over the last five days, 125t has been mined and processed Multiple mining fronts ...

This panel was filmed on 9 September 2025. Predicting the future is no small task, especially in the increasingly fast-moving world we find ourselves in. Trying to find the investments that will ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Vertex Minerals Ltd. ( (AU:VTX)) just ...

Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multitarget drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.

Vertex Pharmaceuticals commits $45 million upfront to leverage Enlaza Therapeutics’ War-Lock platform to create drug conjugates and T cell engagers for autoimmune diseases and gentler conditioning for ...

Vertex Pharma ceuticals CEO Reshma Kewalramani bought a big chunk of the biotech’s stock earlier this month. The move, her first open-market purchase in years, appears to be a show of confidence in ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Vertex Pharmaceuticals stock was among the worst performer in the S&P 500 index early Tuesday after the drugmaker said it wouldn’t advance its next-generation pain medicine to late stage trials.

Vertex Pharmaceuticals made its name and fortune by developing ever more effective medicines for the rare disease cystic fibrosis. On Monday, the biotechnology company disclosed two setbacks that ...

Vertex Pharmaceuticals’VRTX2.65%increase; green up pointing triangle stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into ...